HHV-6 and HHV-7 in Cardiovascular Diseases and Cardiomyopathies

Laßner, Dirk; Krueger, G. R. F.; Buja, L. Maximilian; Kuehl, Uwe

doi:10.1016/b978-0-444-62703-2.00016-1

Cited by 1 publication

(2 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In about 1% of all EMBs, HHV6 could be detected with persistent high viral loads (over 50.000 copies per µg myocardial DNA) characteristic for ciHHV-6. Cardiac complaints and general physical disability improve upon antiviral medication that reduces HHV6 reactivation [28] [33].…”

Section: Current Biopsy-based Treatment Decisionsmentioning

confidence: 99%

See 1 more Smart Citation

Myocarditis—Personalized Medicine by Expanded Endomyocardial Biopsy Diagnostics

Laßner¹,

Rohde²,

Siegismund³

et al. 2014

WJCD

Self Cite

View full text Add to dashboard Cite

Myocarditis and dilated cardiomyopathy (DCM) are acute or chronic disorders of myocardium. The gold standard for final confirmation of causative reasons of these heart muscle diseases is the endomyocardial biopsy (EMB) analysis. Due to focal pathology, diagnostics are failing if the EMB does not contain the area of interest. Personalized medicine comprises the genetic information together with the phenotypic and environmental factors to yield a tailored healthcare for each individual and removes the limitations of the "one-size-fits-all" therapy approach. This provides the opportunity to translate therapies from bench to bedside, to diagnose and predict disease, and to improve patient-tailored treatments based on the unique signatures of a patient's disease. Furthermore, novel treatment schedules can be identified which have eventually the chance to enhance long-term survivals. Global biomarkers such as specific gene expression signatures or miRNA profiles not only have the potential to reduce this problem but also add valuable information for individualized therapy decisions. In future, multiplex approaches allowing rapid and absolutely reliable identification of inflammatory or virally-induced myocardial diseases will replace singleplex methods such as direct detection of viral genomes in one single biopsy. Gene or miRNA profiles are upcoming diagnostic biomarkers for cardiomyopathies which are not only detectable in tissue samples but in body fluids as well. Consequently, a systemic diagnostic approach by determination of distinct expression pattern in e.g., peripheral blood samples will support the characterization of distinct cardiomyopathies by means of non-invasive methods.

show abstract

Section: Current Biopsy-based Treatment Decisionsmentioning

confidence: 99%

“…Myocardial function is affected by virus associated inflammation in case of vasculotropic viruses, e.g., erythrovirus or herpesvirus. Infarct like symptoms in these diseases are often induced by injury of the vascular endothelium [28] [34] [51] [52].…”

Section: Diagnosis and Prognosis Of Myocarditis And Inflammatory Cardmentioning

confidence: 99%